Current Liabilities decreased faster than Genprex Inc 's Cash & cash equivalent, this led to improvement in Genprex Inc 's Quick Ratio to 6.47, Quick Ratio remained below Genprex Inc average.

Within Major Pharmaceutical Preparations industry 156 other companies have achieved higher Quick Ratio than Genprex Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 786, from total ranking in the first quarter 2026 at 1235.

Explain Quick Ratio?
How much Cash & cash equivalents GNPX�s has?
What are GNPX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GNPX/financial-strength

https://api.csimarket.com/api/v1/companies/GNPX/fundamentals

https://api.csimarket.com/api/v1/companies/GNPX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

GNPX Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-3.88 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	1025.16 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	6.47	Subscribe	Subscribe	Subscribe	Subscribe
GNPX's Total Ranking	# 786	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-30.17 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-16.04 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 157
Healthcare Sector	# 252
Overall Market	# 682

Quick Ratio Statistics
High	Average	Low
92.27	17.07	0.02
(Jun 30 2020)		(Mar 31 2018)

Financial Statements
Genprex Inc 's Current Liabilities	$ 2 Millions	Visit GNPX's Balance sheet
Genprex Inc 's Cash & cash equivalent	$ 15 Millions	Visit GNPX's Balance sheet
Source of GNPX's Sales		Visit GNPX's Sales by Geography

Cumulative Genprex Inc 's Quick Ratio

GNPX's Quick Ratio for the trailling 12 Months

GNPX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	11.77 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	433.04 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	4.04	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3708	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-0.9 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	48.74 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to GNPX Financial Strength Comparisons >> Go to Compare GNPX Quick Ratio to its Competitors

On the trailing twelve months basis GNPX Cash & cash equivalent more than doubled by 1025.16 % in Q2 2026 year on year, while Current Liabilities plummeted to $2 millions, this led to increase in in Genprex Inc 's Quick Ratio to 4.04, Quick Ratio remained below GNPX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 424 other companies have achieved higher Quick Ratio than Genprex Inc . While Quick Ratio overall ranking has improved so far to 3708, from total ranking during the twelve months ending first quarter 2026 at 3802.

Explain Quick Ratio?
How much Cash & cash equivalents GNPX�s has?
What are GNPX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 425
Healthcare Sector	# 867
Within the Market	# 3708

trailing twelve months Quick Ratio Statistics
High	Average	Low
69.99	15.99	0.03
(Mar 31 2021)		(Mar 31 2018)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Sellas Life Sciences Group Inc	17.29	$ 138.443 Millions	$ 8.006 Millions
Whitehawk Therapeutics Inc	17.17	$ 190.000 Millions	$ 11.069 Millions
Forte Biosciences Inc	17.12	$ 347.331 Millions	$ 20.289 Millions
Ovid Therapeutics Inc	17.01	$ 169.769 Millions	$ 9.980 Millions
Bioage Labs Inc	16.59	$ 318.745 Millions	$ 19.217 Millions
Olema Pharmaceuticals Inc	16.48	$ 873.571 Millions	$ 53.014 Millions
Erasca Inc	16.41	$ 610.496 Millions	$ 37.200 Millions
Janux Therapeutics Inc	16.14	$ 970.913 Millions	$ 60.152 Millions
Edgewise Therapeutics inc	15.86	$ 460.709 Millions	$ 29.042 Millions
Corvus Pharmaceuticals Inc	15.74	$ 215.200 Millions	$ 13.672 Millions
Telomir Pharmaceuticals Inc	15.55	$ 5.170 Millions	$ 0.332 Millions
Rapport Therapeutics Inc	15.34	$ 436.077 Millions	$ 28.424 Millions
Lb Pharmaceuticals Inc	15.32	$ 369.576 Millions	$ 24.128 Millions
Anixa Biosciences Inc	15.09	$ 26.330 Millions	$ 1.745 Millions
Siga Technologies Inc	14.99	$ 117.584 Millions	$ 7.845 Millions
Vyne Therapeutics Inc	14.87	$ 22.925 Millions	$ 1.542 Millions
Alto Neuroscience Inc	14.64	$ 243.733 Millions	$ 16.652 Millions
Tenax Therapeutics Inc	14.62	$ 118.000 Millions	$ 8.073 Millions
Jade Biosciences Inc	14.61	$ 461.205 Millions	$ 31.570 Millions
Immunome Inc	14.56	$ 519.996 Millions	$ 35.713 Millions
Sensei Biotherapeutics Inc	14.54	$ 186.441 Millions	$ 12.824 Millions
Cytokinetics Incorporated	14.39	$ 2,610.415 Millions	$ 181.429 Millions
Canton Strategic Holdings Inc	14.18	$ 37.242 Millions	$ 2.626 Millions
An2 Therapeutics Inc	14.04	$ 78.387 Millions	$ 5.585 Millions
Aclaris Therapeutics Inc	13.97	$ 394.443 Millions	$ 28.241 Millions
Pmv Pharmaceuticals Inc	13.85	$ 146.393 Millions	$ 10.568 Millions
Generate Biomedicines Inc	13.76	$ 779.456 Millions	$ 56.636 Millions
Braveheart Bio, Inc.	13.56	$ 122.831 Millions	$ 9.058 Millions
First Tracks Biotherapeutics Inc	13.50	$ 168.018 Millions	$ 12.447 Millions
Arrivent Biopharma inc	13.41	$ 373.401 Millions	$ 27.844 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.